Patents by Inventor Laura K. Shawyer

Laura K. Shawyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
    Publication number: 20030191162
    Abstract: The present invention relates to 3-heteroarylidenyl-2-indolinone compounds that modulate the enzymatic activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. Furthermore, these compounds are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer.
    Type: Application
    Filed: December 2, 2002
    Publication date: October 9, 2003
    Applicant: Sugen Inc.
    Inventors: Peter J. Langecker, Laura K. Shawyer, Peng Cho Tang, Li Sun, Alison Lennox Hannah, David Kevin Kwok
  • Treatment of platelet derived growth factor related disorders such as cancers
    Patent number: 6331555
    Abstract: The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: December 18, 2001
    Assignees: University of California, Yissum Research Development Company of the Hebrew University of Jerusalem, Biosignal LTD, Sugen, Inc., Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Klaus P. Hirth, Elaina Mann, Laura K. Shawyer, Axel Ullrich, Istvan Szekely, Tamas Bajor, Janis Haimichael, Laszlo Orfi, Alex Levitzki, Aviv Gazit, Peng Cho Tang, Reiner Lammers